Molecular Partners Ag (MOLN) - News Archive

Breakthrough and Challenges: Molecular Partners Unveils Pioneering Preclinical Data Amidst Financial Hurdles ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass. November 3, 2025 In an exciting development for the field of...

In the ever-evolving field of cancer immunotherapy, the search for innovative therapies that precisely target tumor cells while minimizing collateral damage to healthy tissue remains a paramount goal. A pioneering strid...

Molecular Partners AG, a prominent player in the biotechnology sector specializing in innovative protein therapies, has recently announced the pricing of an underwritten public offering of American Depositary Shares (AD...

Molecular Partners AG, a leading clinical-stage biotech company based in Zurich-Schlieren, Switzerland, continues to break new ground in the field of protein therapeutics through its innovative platform utilizing Design...

In recent years, the biotech industry has witnessed significant advancements in the development of innovative protein drugs. One company at the forefront of this exciting field is Molecular Partners AG (NASDAQ: MOLN). W...

Molecular Partners Presents Promising Data on DARPin Therapeutics Across Multiple Fronts at International Conferences and Publications ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., June 1-14, 2024 - Molecular Partne...

Molecular Partners and Orano Med Report Promising Preclinical Data on Novel Radiopharmaceuticals June 11, 2024 - Zurich-Schlieren, Switzerland, Concord, Mass., and Paris - Molecular Partners(https://www.globenewswire.co...

Molecular Partners, a pioneering clinical-stage biotech company, recently disclosed the positive outcomes of its Phase 1 dose-escalation study of MP0317 at the American Society of Clinical Oncology (ASCO) Annual Meeting...

Molecular Partners Faces Financial Challenges Amid Promising PipelineZURICH-SCHLIEREN, Switzerland and CONCORD, Mass. – Molecular Partners AG, a clinical-stage biotech company specializing in DARPin therapeutics, recent...

Molecular Partners AG, a trailblazing biotechnical firm based in Zurich-Schlieren, Switzerland, and Concord, Massachusetts, has had an enlightening research on preclinical data related to their inevitable therapeutic br...

Molecular Partners and Orano Med Team Up to Develop Cutting-Edge Radio-DARPin Therapies to Combat CancerZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., and PARIS, Jan. 05, 2024 - In a significant move towards innovati...